Atezolizumabe
Also known as MPDL3280A, anti-PDL1, Tecentriq
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Key facts
- Drug.type
- mab
- Drug.image
- Atezolizumab_PD-L1_5X8L.png
- Drug.caption
- Antigen-binding fragment of atezolizumab (blue) in complex with PD-L1 (pink). .
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- PD-L1
- Drug.tradename
- Tecentriq, Tecentriq SC
- Drug.MedlinePlus
- a616035
- Drug.DailyMedID
- Atezolizumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous infusion, subcutaneous
- Drug.class
- Antineoplastic
Article · Português
Atezolizumab ou atezolizumabe, comercializado sob a marca Tecentriq, é um medicamento de anticorpos monoclonais usado no tratamento de carcinoma urotelial, carcinoma de pulmão de células não pequenas, cancro da mama triplo negativo, carcinoma de células pequenas e carcinoma hepatocelular. Atua pela sua ligação a proteína - pProgrammed cell death-ligand 1 - (que reduz a função das células imunes) presente na superfície de diversas células cancerosas, o que aumenta a potência do sistema imune para combater células cancerosas.
Abstract from DBpedia / Wikipedia · CC BY-SA
Gallery (3)
Connections
Categories
Antineoplastic drugsChemicals that do not have a ChemSpider ID assignedDrugs developed by GenentechDrugs developed by Hoffmann-La RocheDrugs that are a monoclonal antibodyDrugs with non-standard legal statusMonoclonal antibodies for tumorsOrphan drugsSource attributionWorld Health Organization essential medicines